GlassScriptPhysician profile
Ryan P Brogan
NPI 1518476498
$5,215.20
in general payments reported to CMS, 2019-2025
27 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $1,007 · 2023: $1,137 · 2024: $1,248 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.17 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $531.71 | 2021-2025 | |
| Amgen INC. | $498.11 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $470.41 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $467.30 | 2021-2025 | Ozempic, Wegovy |
| Pfizer INC. | $457.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $453.38 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Alnylam Pharmaceuticals INC. | $331.92 | 2021-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $223.59 | 2022-2025 | Camzyos |
| Esperion Therapeutics, INC. | $197.49 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $184.98 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Kiniksa Pharmaceuticals International, Plc | $137.29 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $117.01 | 2022-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $109.85 | 2022-2023 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $74.80 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $67.64 | 2023-2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $61.06 | 2024 | Opsumit |
| Glaxosmithkline, LLC. | $59.86 | 2021-2025 | Trelegy Ellipta |
| Lexicon Pharmaceuticals, INC. | $46.14 | 2023 | Inpefa |
| Heartflow, INC. | $34.32 | 2023 | Ffrct |
| Amarin Pharma, INC. | $32.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.69 | 2021 | |
| Philips North America LLC | $23.76 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.12 | 2021 | |
| Lilly USA, LLC | $14.37 | 2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $13.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.